These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 1657845)

  • 1. Variable low dose rate irradiation (131I-anti-CEA) and integrated low dose chemotherapy in the treatment of nonresectable primary intrahepatic cholangiocarcinoma.
    Stillwagon GB; Order SE; Haulk T; Herpst J; Ettinger DS; Fishman EK; Klein JL; Leichner PK
    Int J Radiat Oncol Biol Phys; 1991 Nov; 21(6):1601-5. PubMed ID: 1657845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-modality treatment of primary nonresectable intrahepatic cholangiocarcinoma with 131I anti-CEA--a Radiation Therapy Oncology Group Study.
    Stillwagon GB; Order SE; Klein JL; Leichner PK; Leibel SA; Siegelman SS; Fishman EK; Ettinger DS; Haulk T; Kopher K
    Int J Radiat Oncol Biol Phys; 1987 May; 13(5):687-95. PubMed ID: 3032877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative tumor dose from 131I-labeled polyclonal anti-ferritin, anti-AFP, and anti-CEA in primary liver cancers.
    Leichner PK; Klein JL; Fishman EK; Siegelman SS; Ettinger DS; Order SE
    Cancer Drug Deliv; 1984; 1(4):321-8. PubMed ID: 6085756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival results among patients with alpha-fetoprotein-positive, unresectable hepatocellular carcinoma: analysis of three sequential treatments of the RTOG and Johns Hopkins Oncology Center.
    Abrams RA; Pajak TF; Haulk TL; Flam M; Asbell SO
    Cancer J Sci Am; 1998; 4(3):178-84. PubMed ID: 9612600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type.
    Behr TM; Wulst E; Radetzky S; Blumenthal RD; Dunn RM; Gratz S; Rave-Fränk M; Schmidberger H; Raue F; Becker W
    Cancer Res; 1997 Dec; 57(23):5309-19. PubMed ID: 9393755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospects of radioimmunotherapy in epithelial ovarian cancer: results with iodine-131-labeled murine and humanized MN-14 anti-carcinoembryonic antigen monoclonal antibodies.
    Juweid M; Swayne LC; Sharkey RM; Dunn R; Rubin AD; Herskovic T; Goldenberg DM
    Gynecol Oncol; 1997 Dec; 67(3):259-71. PubMed ID: 9441773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I/II trial of combined 131I anti-CEA monoclonal antibody and hyperthermia in patients with advanced colorectal adenocarcinoma.
    Mittal BB; Zimmer MA; Sathiaseelan V; Benson AB; Mittal RR; Dutta S; Rosen ST; Spies SM; Mettler JM; Groch MW
    Cancer; 1996 Nov; 78(9):1861-70. PubMed ID: 8909304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iodine 131 antiferritin, a new treatment modality in hepatoma: a Radiation Therapy Oncology Group study.
    Order SE; Stillwagon GB; Klein JL; Leichner PK; Siegelman SS; Fishman EK; Ettinger DS; Haulk T; Kopher K; Finney K
    J Clin Oncol; 1985 Dec; 3(12):1573-82. PubMed ID: 2415692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radioimmunotherapy of small volume disease of colorectal cancer metastatic to the liver: preclinical evaluation in comparison to standard chemotherapy and initial results of a phase I clinical study.
    Behr TM; Salib AL; Liersch T; Béhé M; Angerstein C; Blumenthal RD; Fayyazi A; Sharkey RM; Ringe B; Becker H; Wörmann B; Hiddemann W; Goldenberg DM; Becker W
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3232s-3242s. PubMed ID: 10541369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant radioimmunotherapy trial with iodine-131-labeled anti-carcinoembryonic antigen monoclonal antibody F6 F(ab')2 after resection of liver metastases from colorectal cancer.
    Ychou M; Azria D; Menkarios C; Faurous P; Quenet F; Saint-Aubert B; Rouanet P; Pèlegrin M; Bascoul-Mollevi C; Guerreau D; Saccavini JC; Mach JP; Artus JC; Pèlegrin A
    Clin Cancer Res; 2008 Jun; 14(11):3487-93. PubMed ID: 18519781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase-I/II radio-immunotherapy study with Iodine-131-labeled anti-CEA monoclonal antibody F6 F(ab')2 in patients with non-resectable liver metastases from colorectal cancer.
    Ychou M; Pelegrin A; Faurous P; Robert B; Saccavini JC; Guerreau D; Rossi JF; Fabbro M; Buchegger F; Mach JP; Artus JC
    Int J Cancer; 1998 Feb; 75(4):615-9. PubMed ID: 9466665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer.
    Welt S; Divgi CR; Kemeny N; Finn RD; Scott AM; Graham M; Germain JS; Richards EC; Larson SM; Oettgen HF
    J Clin Oncol; 1994 Aug; 12(8):1561-71. PubMed ID: 8040668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized prospective trial comparing full dose chemotherapy to 131I antiferritin: an RTOG study.
    Order S; Pajak T; Leibel S; Asbell S; Leichner P; Ettinger D; Stillwagon G; Herpst J; Haulk T; Kopher K
    Int J Radiat Oncol Biol Phys; 1991 May; 20(5):953-63. PubMed ID: 1850722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
    Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
    Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiotherapy of cholangiocarcinoma: the roles for primary and adjuvant therapies.
    Shiina T; Mikuriya S; Uno T; Toita T; Serizawa S; Itami J; Kawai S; Tani M
    Cancer Chemother Pharmacol; 1992; 31 Suppl():S115-8. PubMed ID: 1333898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of hematologic toxicity after radioimmunotherapy with (131)I-labeled anticarcinoembryonic antigen monoclonal antibodies.
    Juweid ME; Zhang CH; Blumenthal RD; Hajjar G; Sharkey RM; Goldenberg DM
    J Nucl Med; 1999 Oct; 40(10):1609-16. PubMed ID: 10520699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioimmunotherapy of small-volume disease of metastatic colorectal cancer.
    Behr TM; Liersch T; Greiner-Bechert L; Griesinger F; Béhé M; Markus PM; Gratz S; Angerstein C; Brittinger G; Becker H; Goldenberg DM; Becker W
    Cancer; 2002 Feb; 94(4 Suppl):1373-81. PubMed ID: 11877768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing tumors.
    Behr TM; Sharkey RM; Juweid MI; Dunn RM; Ying Z; Zhang CH; Siegel JA; Gold DV; Goldenberg DM
    Cancer Res; 1996 Apr; 56(8):1805-16. PubMed ID: 8620497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG.
    Behr TM; Sharkey RM; Juweid ME; Dunn RM; Vagg RC; Ying Z; Zhang CH; Swayne LC; Vardi Y; Siegel JA; Goldenberg DM
    J Nucl Med; 1997 Jun; 38(6):858-70. PubMed ID: 9189130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repeated adjuvant anti-CEA radioimmunotherapy after resection of colorectal liver metastases: Safety, feasibility, and long-term efficacy results of a prospective phase 2 study.
    Sahlmann CO; Homayounfar K; Niessner M; Dyczkowski J; Conradi LC; Braulke F; Meller B; Beißbarth T; Ghadimi BM; Meller J; Goldenberg DM; Liersch T
    Cancer; 2017 Feb; 123(4):638-649. PubMed ID: 27763687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.